{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:02:03Z","timestamp":1794862923732,"version":"4.9.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"General Project of National Natural Science Foundation of China","award":["81970180"],"award-info":[{"award-number":["81970180"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key Science and Technology Support Project of Tianjin Science and Technology Bureau","award":["20YFZCSY00800"],"award-info":[{"award-number":["20YFZCSY00800"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Relapsed\u00a0or\u00a0refractory\u00a0(R\/R)\u00a0acute\u00a0myeloid\u00a0leukemia\u00a0(AML) has a\u00a0poor\u00a0prognosis. In this study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults with R\/R AML patients. Patients received conditioning chemotherapy with cyclophosphamide (500\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) and fludarabine (30\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) for 3\u00a0days and an infusion of a dose of 1\u20132\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    CAR-T cells\/kg. The incidence of dose-limiting toxicity was the primary endpoint. Ten patients were treated, and all developed cytokine release syndrome (CRS); 4 cases were low-grade, while the remaining 6 were considered high-grade CRS. No patient developed CAR-T cell-related encephalopathy syndrome (CRES). Severe pancytopenia occurred in all patients. Two patients died of severe infection due to chronic agranulocytosis. The complete response (CR)\/CR with\u00a0incomplete\u00a0hematologic\u00a0recovery (CRi) rate was 70% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20097\/10). The median follow-up time was 173\u00a0days (15\u2013488), and 6 patients were alive at the end of the last follow-up. CAR-T cells showed peak expansion within 2\u00a0weeks. Notably, CLL-1 is also highly expressed in normal granulocytes, so bridging hematopoietic stem cell transplantation (HSCT) may be a viable strategy to rescue long-term agranulocytosis due to off-target toxicity. In conclusion, this study is the first to demonstrate the positive efficacy and tolerable safety of CLL-1 CAR-T cell therapy in adult R\/R AML.\n                  <\/jats:p>","DOI":"10.1186\/s13045-022-01308-1","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T11:03:46Z","timestamp":1657191826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1186","volume":"15","author":[{"given":"Xin","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"1308_CR1","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","volume":"29","author":"C Rollig","year":"2011","unstructured":"Rollig C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758\u201365. https:\/\/doi.org\/10.1200\/JCO.2010.32.8500.","journal-title":"J Clin Oncol"},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021011694","volume":"138","author":"JE Rubnitz","year":"2021","unstructured":"Rubnitz JE, Kaspers GJL. How I treat pediatric acute myeloid leukemia. Blood. 2021;138:1009\u201318. https:\/\/doi.org\/10.1182\/blood.2021011694.","journal-title":"Blood"},{"key":"1308_CR3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1683","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH. Next-generation CAR T-cell therapies. Cancer Discov. 2022. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1683.","journal-title":"Cancer Discov"},{"key":"1308_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute Myeloid Leukemia: state of the art and future directions. Front Oncol. 2020;10:697. https:\/\/doi.org\/10.3389\/fonc.2020.00697.","journal-title":"Front Oncol"},{"key":"1308_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030497","author":"J Marvin-Peek","year":"2022","unstructured":"Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. Challenges and advances in chimeric antigen receptor therapy for acute Myeloid Leukemia. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030497.","journal-title":"Cancers (Basel)"},{"key":"1308_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26\u201333. https:\/\/doi.org\/10.1016\/j.blre.2018.10.003.","journal-title":"Blood Rev"},{"key":"1308_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol. 2018;11:7. https:\/\/doi.org\/10.1186\/s13045-017-0553-5.","journal-title":"J Hematol Oncol"},{"key":"1308_CR8","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","volume":"25","author":"H Tashiro","year":"2017","unstructured":"Tashiro H, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Mol Ther. 2017;25:2202\u201313. https:\/\/doi.org\/10.1016\/j.ymthe.2017.05.024.","journal-title":"Mol Ther"},{"key":"1308_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112259","author":"E Laborda","year":"2017","unstructured":"Laborda E, et al. Development of A chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18112259.","journal-title":"Int J Mol Sci"},{"key":"1308_CR10","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin Cancer Res. 2021;27:3549\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4543.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01308-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01308-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01308-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T11:03:52Z","timestamp":1657191832000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01308-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01308-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Tianjin First Central Hospital and was registered for clinical trials in the China Clinical Trial Registration Center (Trial registration: ChiCTR2000041054. Registered 17 December 2020,\n                      \n                      ). All patients signed an informed consent form. The animal experiment protocol was approved by the Animal Care and Use Committee of Tianjin Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed informed consent and also consented to the publication of these data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}